[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Crinetics Pharmaceuticals Inc (CRNX)

Crinetics Pharmaceuticals Inc (CRNX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,748,392
  • Shares Outstanding, K 105,440
  • Annual Sales, $ 7,700 K
  • Annual Income, $ -465,320 K
  • EBIT $ -545 M
  • EBITDA $ -556 M
  • 60-Month Beta 0.28
  • Price/Sales 493.36
  • Price/Cash Flow N/A
  • Price/Book 2.96

Options Overview Details

View History
  • Implied Volatility 59.59% (+2.25%)
  • Historical Volatility 58.73%
  • IV Percentile 35%
  • IV Rank 35.47%
  • IV High 95.22% on 12/17/25
  • IV Low 40.01% on 08/15/25
  • Expected Move (DTE 17) 3.36 (9.44%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 6
  • Volume Avg (30-Day) 116
  • Put/Call OI Ratio 0.73
  • Today's Open Interest 2,198
  • Open Int (30-Day) 2,059
  • Expected Range 32.19 to 38.91

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-1.22
  • Number of Estimates 7
  • High Estimate $-1.04
  • Low Estimate $-1.35
  • Prior Year $-1.23
  • Growth Rate Est. (year over year) +0.81%

Price Performance

See More
Period Period Low Period High Performance
1-Month
33.89 +4.90%
on 05/19/26
43.62 -18.50%
on 05/07/26
-2.89 (-7.52%)
since 04/29/26
3-Month
33.10 +7.40%
on 03/30/26
43.62 -18.50%
on 05/07/26
-5.55 (-13.50%)
since 02/27/26
52-Week
25.83 +37.63%
on 08/08/25
57.99 -38.70%
on 01/05/26
+5.64 (+18.86%)
since 05/28/25

Most Recent Stories

More News
Crinetics Pharmaceuticals to Participate in Jefferies Global Healthcare Conference 2026

SAN DIEGO, May 22, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that company management will participate in the Jefferies Global Healthcare Conference,...

CRNX : 35.55 (-1.28%)
Crinetics Pharmaceuticals Q1 Earnings Call Highlights

Crinetics Pharmaceuticals (NASDAQ:CRNX) reported first-quarter 2026 results highlighting early commercial traction for its newly launched acromegaly treatment PALSONIFY and continued investment in a broad...

CRNX : 35.55 (-1.28%)
Crinetics Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update

      PALSONIFY™ (Paltusotine) Net Product Revenue of $10.3 Million for First-Quarter 2026, with 232 Enrollment Forms in the First Quarter        Management Hosting Conference Call at...

CRNX : 35.55 (-1.28%)
Crinetics' First Commercial Quarter Tests Whether Acromegaly Launch Math Holds Beyond Trial Data

Barchart Research What to Expect from CRNX Earnings CRNX Generated May 6, 2026 Current Price $41.71 EPS Estimate $$-1.22 Consensus Rating Strong Buy Average Move 5.11% Crinetics' First Commercial Quarter...

CRNX : 35.55 (-1.28%)
Crinetics Pharmaceuticals Announces the European Commission Approval of PALSONIFY® (Paltusotine) for the Treatment of Acromegaly in Adults

PALSONIFY is the first once-daily, oral therapy approved to treat acromegaly in the European Union Approval based on strength of data from two pivotal Phase 3 studies studying PALSONIFY in both medical...

CRNX : 35.55 (-1.28%)
Crinetics Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026

SAN DIEGO, April 08, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report first quarter 2026 financial results on Thursday, May 7, 2026 after...

CRNX : 35.55 (-1.28%)
Crinetics Pharmaceuticals Announces Submission of Marketing Authorization Application in Brazil for Palsonifyâ„¢ (Paltusotine) in Acromegaly

SAN DIEGO, March 26, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced the submission of a Marketing Authorization Application (MAA) to Brazil’s National Health...

CRNX : 35.55 (-1.28%)
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

PALSONIFY™ (Paltusotine) Net Product Revenue of $5.4 Million for Fourth-Quarter 2025, with >200 Enrollment Forms at the End of December        Operationally Seamless Phase 2/3 Study of Atumelnant...

CRNX : 35.55 (-1.28%)
Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences in March

SAN DIEGO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that company management will participate in the following two upcoming investor conferences:...

CRNX : 35.55 (-1.28%)
Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

SAN DIEGO, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report fourth quarter and full year 2025 financial results on Thursday, February...

CRNX : 35.55 (-1.28%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strongest short term outlook on maintaining the current direction.

See More Share

Business Summary

CRINETICS PHARMACEUTICALS is a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors. CRINETICS PHARMACEUTICALS is based in SAN DIEGO.

See More

Key Turning Points

3rd Resistance Point 37.70
2nd Resistance Point 36.96
1st Resistance Point 36.26
Last Price 35.55
1st Support Level 34.82
2nd Support Level 34.08
3rd Support Level 33.38

See More

52-Week High 57.99
Fibonacci 61.8% 45.70
Fibonacci 50% 41.91
Fibonacci 38.2% 38.12
Last Price 35.55
52-Week Low 25.83

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.